A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- High Grade Serous Ovarian CancerTriple Negative Breast CancerEndometrial Cancer
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- A2A Pharmaceuticals Inc.
- Target Recruit Count
- 144
- Registration Number
- NCT06136884
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Oklahoma Univeristy, Oklahoma City, Oklahoma, United States
🇺🇸Mary Crowley Cancer Research, Dallas, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath